IL130656A0 - Soluble CTLA4 mutant molecules - Google Patents

Soluble CTLA4 mutant molecules

Info

Publication number: IL130656A0
Authority: IL; Israel
Prior art keywords: mutant molecules; soluble ctla4; ctla4 mutant; soluble; molecules
Prior art date: 1997-01-31

Application number

IL13065698A

Other languages

English (en)

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-31

Filing date

1998-01-29

Publication date

2000-06-01

1998-01-29 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2000-06-01 Publication of IL130656A0 publication Critical patent/IL130656A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL13065698A 1997-01-31 1998-01-29 Soluble CTLA4 mutant molecules IL130656A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3659497P	1997-01-31	1997-01-31
PCT/US1998/001880 WO1998033513A1 (en)	1997-01-31	1998-01-29	Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number	Publication Date
IL130656A0 true IL130656A0 (en)	2000-06-01

Family

ID=21889481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13065698A IL130656A0 (en)	1997-01-31	1998-01-29	Soluble CTLA4 mutant molecules

Country Status (17)

Country	Link
US (2)	US20030035816A1 (xx)
EP (2)	EP1557173A1 (xx)
JP (1)	JP2001510473A (xx)
KR (1)	KR20000070633A (xx)
CN (1)	CN1244803A (xx)
AR (1)	AR007225A1 (xx)
AU (1)	AU725016B2 (xx)
BR (1)	BR9806764A (xx)
CA (1)	CA2278771A1 (xx)
HU (1)	HUP0001971A3 (xx)
IL (1)	IL130656A0 (xx)
NO (1)	NO993708L (xx)
NZ (1)	NZ336009A (xx)
PL (1)	PL334898A1 (xx)
RU (2)	RU2235555C2 (xx)
WO (1)	WO1998033513A1 (xx)
ZA (1)	ZA98533B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6887471B1 (en)	1991-06-27	2005-05-03	Bristol-Myers Squibb Company	Method to inhibit T cell interactions with soluble B7
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP4751493B2 (ja) *	1996-03-20	2011-08-17	ブリストル−マイヤーズスクイッブカンパニー	Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
AUPP221098A0 (en)	1998-03-06	1998-04-02	Diatech Pty Ltd	V-like domain binding molecules
IL150571A0 (en) *	2000-01-03	2003-02-12	Tr Associates L L C	Novel chimeric proteins and methods for using the same
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
CN1309735C (zh) *	2000-05-26	2007-04-11	布里斯托尔-迈尔斯斯奎布公司	可溶性ctla4突变体分子及其应用
CA2411962A1 (en) *	2000-06-09	2001-12-20	Bristol-Myers Squibb Company	Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DE60135029D1 (de)	2000-07-03	2008-09-04	Bristol Myers Squibb Co	Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
JP2004535364A (ja) *	2001-01-26	2004-11-25	エモリー・ユニバーシティ	臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
WO2002094202A2 (en)	2001-05-23	2002-11-28	Bristol-Myers Squibb Company	Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
IL149701A0 (en) *	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
EP1496931A4 (en) *	2002-04-19	2009-07-01	Bristol Myers Squibb Co	METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
MXPA05006523A (es) *	2002-12-23	2005-08-26	Squibb Bristol Myers Co	Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
KR101088223B1 (ko) *	2002-12-23	2011-11-30	브리스톨-마이어스 스큅 컴퍼니	단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상
US7307064B2 (en) *	2003-08-04	2007-12-11	Bristol-Myers Squibb Company	Methods for treating cardiovascular disease using a soluble CTLA4 molecule
AU2004287431B2 (en)	2003-10-27	2010-03-11	Amgen Inc.	Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CA2836123C (en)	2005-12-20	2017-09-12	Bristol-Myers Squibb Company	Compositions and methods for producing a composition
GB0620934D0 (en) *	2006-10-20	2006-11-29	Cambridge Antibody Tech	Protein variants
CA2703263C (en) *	2007-11-01	2014-03-18	Perseid Therapeutics Llc	Immunosuppressive polypeptides and nucleic acids
US7915222B2 (en) *	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
NO2344540T3 (xx)	2008-10-02	2018-04-28
CN102030828B (zh) *	2009-09-25	2014-10-29	上海抗体药物国家工程研究中心有限公司	一种高亲和力的CTLA4-Ig融合蛋白突变体
EP2545073B1 (en)	2010-03-12	2015-09-30	AbbVie Biotherapeutics Inc.	Ctla4 proteins and their uses
AU2011309689B2 (en)	2010-09-28	2015-01-15	Hadasit Medical Research Services & Development Ltd.	Compositions and methods for treatment of hematological malignancies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en) *	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IL92382A (en) *	1988-11-23	1994-12-29	Univ Michigan	Use of a ligand specific for CD28 in the manufacture of medicament
US6905680B2 (en) *	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
WO1993000431A1 (en) *	1991-06-27	1993-01-07	Bristol-Myers Squibb Company	Ctl4a receptor, fusion proteins containing it and uses thereof
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
JP4751493B2 (ja) *	1996-03-20	2011-08-17	ブリストル−マイヤーズスクイッブカンパニー	Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) *	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
CA2411962A1 (en) *	2000-06-09	2001-12-20	Bristol-Myers Squibb Company	Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
DE60135029D1 (de) *	2000-07-03	2008-09-04	Bristol Myers Squibb Co	Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) *	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
JP2004535364A (ja) *	2001-01-26	2004-11-25	エモリー・ユニバーシティ	臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
WO2002094202A2 (en) *	2001-05-23	2002-11-28	Bristol-Myers Squibb Company	Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
KR101088223B1 (ko) *	2002-12-23	2011-11-30	브리스톨-마이어스 스큅 컴퍼니	단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상
MXPA05006523A (es) *	2002-12-23	2005-08-26	Squibb Bristol Myers Co	Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
US7307064B2 (en) *	2003-08-04	2007-12-11	Bristol-Myers Squibb Company	Methods for treating cardiovascular disease using a soluble CTLA4 molecule

1998
- 1998-01-22 ZA ZA9800533A patent/ZA98533B/xx unknown
- 1998-01-26 AR ARP980100329A patent/AR007225A1/es unknown
- 1998-01-28 US US09/014,761 patent/US20030035816A1/en not_active Abandoned
- 1998-01-29 HU HU0001971A patent/HUP0001971A3/hu unknown
- 1998-01-29 AU AU60525/98A patent/AU725016B2/en not_active Ceased
- 1998-01-29 BR BR9806764-8A patent/BR9806764A/pt not_active Application Discontinuation
- 1998-01-29 WO PCT/US1998/001880 patent/WO1998033513A1/en not_active Application Discontinuation
- 1998-01-29 RU RU99119082/15A patent/RU2235555C2/ru not_active IP Right Cessation
- 1998-01-29 KR KR1019997006882A patent/KR20000070633A/ko not_active Ceased
- 1998-01-29 NZ NZ336009A patent/NZ336009A/en unknown
- 1998-01-29 PL PL98334898A patent/PL334898A1/xx not_active Application Discontinuation
- 1998-01-29 CA CA002278771A patent/CA2278771A1/en not_active Abandoned
- 1998-01-29 EP EP04014530A patent/EP1557173A1/en not_active Withdrawn
- 1998-01-29 JP JP53314398A patent/JP2001510473A/ja not_active Ceased
- 1998-01-29 IL IL13065698A patent/IL130656A0/xx unknown
- 1998-01-29 EP EP98903873A patent/EP0988047A4/en active Pending
- 1998-01-29 CN CN98802054A patent/CN1244803A/zh active Pending
1999
- 1999-07-30 NO NO993708A patent/NO993708L/no not_active Application Discontinuation
2003
- 2003-01-30 US US10/356,179 patent/US20040014171A1/en not_active Abandoned
2004
- 2004-05-18 RU RU2004115039/13A patent/RU2004115039A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO993708L (no)	1999-09-28
HUP0001971A2 (hu)	2000-10-28
AU725016B2 (en)	2000-10-05
NZ336009A (en)	2001-06-29
EP0988047A4 (en)	2003-05-14
BR9806764A (pt)	2000-03-14
RU2004115039A (ru)	2005-10-27
JP2001510473A (ja)	2001-07-31
PL334898A1 (en)	2000-03-27
CA2278771A1 (en)	1998-08-06
CN1244803A (zh)	2000-02-16
US20030035816A1 (en)	2003-02-20
HUP0001971A3 (en)	2002-01-28
US20040014171A1 (en)	2004-01-22
AR007225A1 (es)	1999-10-27
KR20000070633A (ko)	2000-11-25
WO1998033513A1 (en)	1998-08-06
NO993708D0 (no)	1999-07-30
EP0988047A1 (en)	2000-03-29
RU2235555C2 (ru)	2004-09-10
EP1557173A1 (en)	2005-07-27
ZA98533B (en)	1999-07-22
AU6052598A (en)	1998-08-25

Publication	Publication Date	Title
IL130656A0 (en)	2000-06-01	Soluble CTLA4 mutant molecules
AU1709299A (en)	1999-06-16	Mixer-injectors
AU9414098A (en)	1998-11-27	Ascorbyl-phosphoryl-cholesterol
AU1027499A (en)	1999-04-23	32P-polyphosphazene
AU4117497A (en)	1999-03-01	Micropolarimeter
AU6998698A (en)	1998-12-10	Dioxacycloalkan-8-one
AU6185898A (en)	1998-09-18	Clavaspirins
AU6525998A (en)	1998-10-22	Improved metallo-endopeptidases
AU8214598A (en)	1999-01-04	3-benzylpiperidine
AU7761998A (en)	1998-12-11	Korrosionsschutzanstrichstoff
AU9183798A (en)	1999-03-22	Catamaran - bicycle - kayak
AU4469997A (en)	1999-04-05	Heregulin-gamma
AU5391798A (en)	1998-08-20	Thiamacrolides
AU5540298A (en)	1998-09-24	Rockbolts
AU7780498A (en)	1998-12-21	Cafetiere
AU8121298A (en)	1999-01-04	G-seat
AU6507298A (en)	1998-09-22	Renovative pipeliner
AU6060598A (en)	1998-10-08	Multi-hopper
AU749312C (en)	2003-03-20	Novel modified tie-2 receptor ligands
HK1025508A (en)	2000-11-17	Soluble ctla4 mutant molecules and uses thereof
PL107388U1 (en)	1998-06-08	Union
AUPO473597A0 (en)	1997-02-20	Toprelease
AUPO501997A0 (en)	1997-03-06	Roofstay
AU9156498A (en)	1999-03-01	Chemo-protection
AU9168398A (en)	1999-04-05	Bowgrip